Full-Time
Develops medicines for serious diseases
No salary listed
Senior, Expert
Munich, Germany
Hybrid
Hybrid-Eligible role allows for remote work up to two days per week.
Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Boston, Massachusetts
Founded
1989
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
Friday's readout at ADA 2025 comes after Vertex axed its cell therapy - device combo VX-264, also being developed for T1D, and swallowed a $400 million impairment charge as a result.
After axing diabetes asset, Vertex lays off 140 staff.
PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.
VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.
Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.